心肌缺血是冠状动脉血流不足导致心肌供氧不足的病理状态，但药物的疗效易受耐受性和不良反应影响。三七皂苷R₁主要来源于五加科植物三七中的原人参二醇型三萜皂苷，可通过减轻心肌炎性损伤，减轻氧化应激损伤，抑制心肌细胞凋亡，调节脂质代谢，延缓心肌重构，促进心肌细胞增殖，改善线粒体功能，促进血管新生发挥抗心肌缺血作用。总结了三七皂苷R₁改善心肌缺血的药理作用研究进展，以期为三七皂苷R₁的基础研究和新药开发提供参考。

Myocardial ischemia is a pathological condition caused by insufficient coronary blood flow leading to inadequate oxygen supply to the myocardium, but the efficacy of drugs is easily affected by tolerance and adverse reactions. Notoginsenoside R₁ primarily originates from the protopanaxadiol-type triterpenoid saponins in Notoginseng Radix et Rhizoma, a plant of the Araliaceae family. Notoginsenoside R₁ exerts anti-myocardial ischemic effects by alleviating myocardial inflammatory damage, reducing oxidative stress injury, inhibiting myocardial cell apoptosis, regulating lipid metabolism, delaying myocardial remodeling, promoting myocardial cell proliferation, improving mitochondrial function, and stimulating angiogenesis. Therefore, this article summarizes the pharmacological research progress of notoginsenoside R₁in improving myocardial ischemia, aiming to provide references for its fundamental research and new drug development.

国家自然科学基金资助项目（82160899）；海南省自然科学基金项目（824MS150）